pre-clinical development

Adiso Therapeutics creates medicines to treat inflammatory diseases, aiming to improve the lives of patients and their families. The company is advancing a pipeline of multi-modal agents with novel mechanisms of action and a precision therapeutic approach, including ADS032, a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for respiratory and dermal inflammation, and ADS024, an orally dosed single-strain live biotherapeutic product.

drug development

Alchemab Therapeutics has developed a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires. Using well-defined patient samples, deep B cell sequencing, and computational analysis, it identifies convergent protective antibody responses among individuals resilient to specific diseases. It is building a pipeline of protective therapeutics for hard-to-treat diseases, initially focused on neurodegenerative conditions and oncology.

antibody discoveryclinical developmentCMCcomputational analysisdeep B cell sequencingdeep learningtoxicology

Alpha Cognition is a commercial stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The company received FDA approval on July 26, 2024 of its New Drug Application for ZUNVEYL (benzgalantamine), previously known as ALPHA-1062 oral tablet formulation, for the treatment of mild-to-moderate Alzheimer's disease.

biopharmaceutical developmentcommercial manufacturingcommercial sales

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer, accompanied by biomarkers to identify patients who will most benefit from each therapeutic antibody. Its programs combine monoclonal antibodies targeting secondary immune checkpoints that regulate myeloid-dependent immune suppression with patient-selection biomarkers based on insights from human patients. The company was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT) to support pre

biomarker developmentmonoclonal antibody developmentprecision oncology

Diorasis Therapeutics is a pre-clinical stage biotech company developing innovative ophthalmology products for common diseases aspiring to prevent blindness. Its lead compound is a first-in-class disease-modifying, gene-agnostic gene therapy for normalizing outflow facility in the trabecular meshwork and decreasing intraocular pressure in patients with open angle glaucoma.

gene therapyophthalmology research